» Articles » PMID: 34633095

AT-rich Interaction Domain 5A Regulates the Transcription of Interleukin-6 Gene in Prostate Cancer Cells

Overview
Journal Prostate
Date 2021 Oct 11
PMID 34633095
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Interleukin-6 (IL-6) is a pleiotropic cytokine that confers androgen-independence and aggressiveness in prostate cancer (PCa); however, the molecular mechanisms regulating IL-6 expression remain unclear. The expression of ARID5A, an AT-rich interaction domain (ARID) DNA-binding motif-containing transcription factor is positively correlated with IL-6 expression in human PCa. We, therefore, hypothesized that ARID5A could regulate IL-6 expression in PCa.

Methods: The relationship between ARID5A and IL-6 in PCa patients was analyzed using statistical analyses of multiple clinical microarray data sets. To investigate whether ARID5A regulates IL-6 expression, CRISPR-driven ARID5A knockout clones were established in DU145 and PC-3 cells.

Results: Analysis of three microarray data sets showed a positive correlation between ARID5A and IL-6 expression. The expression of IL-6 in ARID5A knockout clones was significantly reduced compared with control clones in both PCa cell lines. Knockout of ARID5A did not result in any loss of IL-6 mRNA stability. Instead, we observed a significant decrease in the occupancy of both active RNA Polymerase II and the active histone mark, H3K4me3 at the IL-6 transcriptional start site in ARID5A knockout PCa cells, suggesting a role for transcriptional regulation.

Conclusions: Our study demonstrated that loss of ARID5A downregulates the expression of IL-6 at the transcriptional level.

Citing Articles

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D Oncogene. 2024; 43(43):3197-3213.

PMID: 39266679 PMC: 11493679. DOI: 10.1038/s41388-024-03148-4.


AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.

Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D bioRxiv. 2024; .

PMID: 38766099 PMC: 11100730. DOI: 10.1101/2024.05.07.592966.


Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.

Ren M, Feng L, Zong R, Sun H World J Surg Oncol. 2023; 21(1):257.

PMID: 37605192 PMC: 10464224. DOI: 10.1186/s12957-023-03142-2.


The uncharacterized transcript confers a cachexic phenotype on cancer cells.

Yamakawa T, Zhang G, Najjar L, Li C, Itakura K Oncotarget. 2023; 14:723-737.

PMID: 37477523 PMC: 10360925. DOI: 10.18632/oncotarget.28476.


Recent Advances in the Role of Arid5a in Immune Diseases and Cancer.

Nyati K, Kishimoto T Front Immunol. 2022; 12:827611.

PMID: 35126382 PMC: 8809363. DOI: 10.3389/fimmu.2021.827611.

References
1.
Okamoto M, Lee C, Oyasu R . Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997; 57(1):141-6. View

2.
Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View

3.
Ramalingam S, Ramamurthy V, Njar V . Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. J Steroid Biochem Mol Biol. 2016; 166:16-27. PMC: 7371258. DOI: 10.1016/j.jsbmb.2016.07.006. View

4.
Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E . A proposal for validation of antibodies. Nat Methods. 2016; 13(10):823-7. PMC: 10335836. DOI: 10.1038/nmeth.3995. View

5.
Alcover J, Filella X, Luque P, Molina R, Izquierdo L, Auge J . Prognostic value of IL-6 in localized prostatic cancer. Anticancer Res. 2010; 30(10):4369-72. View